Eisai Company, Ltd. (ESALY.PK) Submits Application To Expand Indication Of Anti-Alzheimer's Agent Aricept® As Treatment For Dementia With Lewy Bodies In Japan  
12/10/2013 11:04:32 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Tokyo, Oct 31, 2013 - (JCN Newswire) - Eisai Co., Ltd. (Headquarters: Tokyo, President & CEO: Haruo Naito), announced today that it has filed an application for the anti-Alzheimer's agent Aricept(R) (donepezil hydrochloride, "donepezil") in Japan, requesting a new indication expansion to use the agent in the treatment of dementia with Lewy bodies (DLB).

Help employers find you! Check out all the jobs and post your resume.